换一批
换一批
作者：
Baoyan,Bai [1]
;
Jillian F,Wise [2]
;
Daniel,Vodák [3]
;
Sigve,Nakken [4]
;
Ankush,Sharma [5]
;
Yngvild Nuvin,Blaker [6]
;
Marianne,Brodtkorb [7]
;
Vera,Hilden [5]
;
Gunhild,Trøen [8]
;
Weicheng,Ren [9]
;
Susanne,Lorenz [10]
;
Michael S,Lawrence [11]
;
Ola,Myklebost [12]
;
Eva,Kimby [13]
;
Qiang,Pan-Hammarström [9]
;
Chloé B,Steen [5]
;
Leonardo A,Meza-Zepeda [14]
;
Klaus,Beiske [8]
;
Erlend B,Smeland [6]
;
Eivind,Hovig [15]
;
Ole Christian,Lingjærde [16]
;
Harald,Holte [17]
;
June Helen,Myklebust [18]
作者单位：
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Clinical Molecular Biology (EpiGen),, Akershus University Hospital, Lørenskog, Norway.
[1]
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.;Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.;Broad Institute of Harvard and MIT, Cambridge, MA, USA.
[2]
Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
[3]
Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.;Centre for Bioinformatics, University of Oslo, Oslo, Norway.
[4]
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.;Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
[5]
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
[6]
KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway.
[7]
Department of Pathology, Oslo University Hospital, Oslo, Norway.
[8]
Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
[9]
Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
[10]
Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.;Broad Institute of Harvard and MIT, Cambridge, MA, USA.
[11]
Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;Department for Clinical Science, University of Bergen, Bergen, Norway.
[12]
Unit for Hematology and Department of Medicine at Karolinska Institutet, Huddinge, Stockholm, Sweden.
[13]
Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
[14]
Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.;Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.;Centre for Bioinformatics, University of Oslo, Oslo, Norway.
[15]
KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Informatics, University of Oslo, Oslo, Norway.;Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
[16]
KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. hhe@ous-hf.no.;Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway. hhe@ous-hf.no.;Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway. hhe@ous-hf.no.
[17]
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. j.h.myklebust@medisin.uio.no.;KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.;Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.
[18]
主题词
人类(Humans);淋巴瘤, 滤泡性(Lymphoma, Follicular);女(雌)性(Female);男(雄)性(Male);突变(Mutation);中年人(Middle Aged);老年人(Aged);基因组学(Genomics);成年人(Adult);DNA拷贝数变异(DNA Copy Number Variations);CREB结合蛋白质(CREB-Binding Protein);纵向研究(Longitudinal Studies);老年人, 80以上(Aged, 80 and over)
DOI
10.1038/s41408-024-01124-5
PMID
39191762
发布时间
2024-11-07
- 浏览0
Blood cancer journal
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
